Viracta Therapeutics, Inc. (VIRX) Misses Q4 EPS by 4c

Viracta Therapeutics, Inc. (NASDAQ: VIRX) reported Q4 EPS of ($0.35), $0.04 worse than the analyst estimate of ($0.31).

For earnings history and earnings-related data on Viracta Therapeutics, Inc. (VIRX) click here.

You May Also Be Interested In

• NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
• Credo Technology Group Holding (CRDO) Tops Q1 EPS by 4c; offers guidance
• Dell Technologies (DELL) Tops Q2 EPS by $2.17, Offers Guidance